# Stryker Corp: financial statements, quarterly

SYK · NYSE · CIK 310764 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/syk.md) · [Financials](/companies/syk/financials.md) · [Filings](/companies/syk/filings.md) · [Insiders](/companies/syk/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/syk/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [5,815](/filings/0000310764-25-000023.md) | [5,243](/filings/0000310764-26-000010.md) | [5,422](/filings/0000310764-26-000010.md) | [5,494](/filings/0000310764-26-000010.md) | [6,436](/filings/0000310764-26-000010.md) | [5,866](/filings/0000310764-26-000031.md) | [6,022](/filings/0000310764-26-000050.md) | [6,057](/filings/0000310764-26-000061.md) | [7,171](/filings/0000310764-26-000010.md) | [6,020](/filings/0000310764-26-000031.md) | [6,589](/filings/0000310764-26-000050.md) | [6,520](/filings/0000310764-26-000061.md) |
| Cost of revenue | $m | [2,112 d](/filings/0000310764-26-000010.md) | [1,910](/filings/0000310764-25-000075.md) | [2,006](/filings/0000310764-25-000107.md) | [1,977](/filings/0000310764-25-000129.md) | [2,262 d](/filings/0000310764-26-000010.md) | [2,122](/filings/0000310764-26-000031.md) | [2,181](/filings/0000310764-26-000050.md) | [2,205](/filings/0000310764-26-000061.md) | [2,543 d](/filings/0000310764-26-000010.md) | [2,210](/filings/0000310764-26-000031.md) | [2,091](/filings/0000310764-26-000050.md) | [2,272](/filings/0000310764-26-000061.md) |
| Gross profit | $m | [3,703](/filings/0000310764-25-000023.md) | [3,333](/filings/0000310764-26-000010.md) | [3,416](/filings/0000310764-26-000010.md) | [3,517](/filings/0000310764-26-000010.md) | [4,174](/filings/0000310764-26-000010.md) | [3,744](/filings/0000310764-26-000031.md) | [3,841](/filings/0000310764-26-000050.md) | [3,852](/filings/0000310764-26-000061.md) | [4,628](/filings/0000310764-26-000010.md) | [3,810](/filings/0000310764-26-000031.md) | [4,498](/filings/0000310764-26-000050.md) | [4,248](/filings/0000310764-26-000061.md) |
| Research and development | $m | [350 d](/filings/0000310764-26-000010.md) | [368](/filings/0000310764-25-000075.md) | [363](/filings/0000310764-25-000107.md) | [377](/filings/0000310764-25-000129.md) | [358 d](/filings/0000310764-26-000010.md) | [405](/filings/0000310764-26-000031.md) | [407](/filings/0000310764-26-000050.md) | [410](/filings/0000310764-26-000061.md) | [401 d](/filings/0000310764-26-000010.md) | [413](/filings/0000310764-26-000031.md) | [434](/filings/0000310764-26-000050.md) | [433](/filings/0000310764-26-000061.md) |
| Selling, general and administrative | $m | [1,911 d](/filings/0000310764-26-000010.md) | [1,837](/filings/0000310764-25-000075.md) | [1,831](/filings/0000310764-25-000107.md) | [1,894](/filings/0000310764-25-000129.md) | [2,123 d](/filings/0000310764-26-000010.md) | [2,300](/filings/0000310764-26-000031.md) | [2,079](/filings/0000310764-26-000050.md) | [2,045](/filings/0000310764-26-000061.md) | [2,227 d](/filings/0000310764-26-000010.md) | [2,281](/filings/0000310764-26-000031.md) | [2,229](/filings/0000310764-26-000050.md) | [2,313](/filings/0000310764-26-000061.md) |
| Operating income | $m | [1,257 d](/filings/0000310764-26-000010.md) | [972](/filings/0000310764-25-000075.md) | [1,051](/filings/0000310764-25-000107.md) | [1,085](/filings/0000310764-25-000129.md) | [581 d](/filings/0000310764-26-000010.md) | [837](/filings/0000310764-26-000031.md) | [1,113](/filings/0000310764-26-000050.md) | [1,135](/filings/0000310764-26-000061.md) | [1,804 d](/filings/0000310764-26-000010.md) | [936](/filings/0000310764-26-000031.md) | [1,659](/filings/0000310764-26-000050.md) | [1,034](/filings/0000310764-26-000061.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | [137](/filings/0000310764-26-000031.md) | [159](/filings/0000310764-26-000050.md) | [157](/filings/0000310764-26-000061.md) | [154 d](/filings/0000310764-26-000010.md) | [148](/filings/0000310764-26-000031.md) | [141](/filings/0000310764-26-000050.md) | [143](/filings/0000310764-26-000061.md) |
| Income tax | $m | [83.0 d](/filings/0000310764-26-000010.md) | [135](/filings/0000310764-25-000075.md) | [173](/filings/0000310764-25-000107.md) | [209](/filings/0000310764-25-000129.md) | [(18.0) d](/filings/0000310764-26-000010.md) | [110](/filings/0000310764-26-000031.md) | [132](/filings/0000310764-26-000050.md) | [170](/filings/0000310764-26-000061.md) | [856 d](/filings/0000310764-26-000010.md) | [105](/filings/0000310764-26-000031.md) | [288](/filings/0000310764-26-000050.md) | [244](/filings/0000310764-26-000061.md) |
| Net income | $m | [1,143](/filings/0000310764-25-000023.md) | [788](/filings/0000310764-26-000010.md) | [825](/filings/0000310764-26-000010.md) | [834](/filings/0000310764-26-000010.md) | [546](/filings/0000310764-26-000010.md) | [654](/filings/0000310764-26-000031.md) | [884](/filings/0000310764-26-000050.md) | [859](/filings/0000310764-26-000061.md) | [849](/filings/0000310764-26-000010.md) | [745](/filings/0000310764-26-000031.md) | [1,276](/filings/0000310764-26-000050.md) | [753](/filings/0000310764-26-000061.md) |
| Diluted EPS | $ per share | [2.98](/filings/0000310764-25-000023.md) | [2.05](/filings/0000310764-26-000010.md) | [2.14](/filings/0000310764-26-000010.md) | [2.16](/filings/0000310764-26-000010.md) | [1.41](/filings/0000310764-26-000010.md) | [1.69](/filings/0000310764-26-000031.md) | [2.29](/filings/0000310764-26-000050.md) | [2.22](/filings/0000310764-26-000061.md) | [2.20](/filings/0000310764-26-000010.md) | [1.93](/filings/0000310764-26-000031.md) | [3.30](/filings/0000310764-26-000050.md) | [1.96](/filings/0000310764-26-000061.md) |
| Basic EPS | $ per share | [3.01](/filings/0000310764-25-000023.md) | [2.07](/filings/0000310764-26-000010.md) | [2.17](/filings/0000310764-26-000010.md) | [2.18](/filings/0000310764-26-000010.md) | [1.43](/filings/0000310764-26-000010.md) | [1.71](/filings/0000310764-26-000031.md) | [2.32](/filings/0000310764-26-000050.md) | [2.25](/filings/0000310764-26-000061.md) | [2.21](/filings/0000310764-26-000010.md) | [1.95](/filings/0000310764-26-000031.md) | [3.32](/filings/0000310764-26-000050.md) | [1.97](/filings/0000310764-26-000061.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [3.0](/filings/0000310764-25-000023.md) | [2.3](/filings/0000310764-24-000064.md) | [1.9](/filings/0000310764-24-000098.md) | [3.9](/filings/0000310764-24-000115.md) | [3.7](/filings/0000310764-26-000010.md) | [2.3](/filings/0000310764-25-000075.md) | [2.4](/filings/0000310764-25-000107.md) | [3.3](/filings/0000310764-25-000129.md) | [4.0](/filings/0000310764-26-000061.md) | [2.9](/filings/0000310764-26-000031.md) | [3.4](/filings/0000310764-26-000050.md) | [3.3](/filings/0000310764-26-000061.md) |
| Current assets | $bn | [12.5](/filings/0000310764-25-000023.md) | [11.9](/filings/0000310764-24-000064.md) | [11.6](/filings/0000310764-24-000098.md) | [14.7](/filings/0000310764-24-000115.md) | [14.8](/filings/0000310764-26-000010.md) | [13.0](/filings/0000310764-25-000075.md) | [13.0](/filings/0000310764-25-000107.md) | [13.7](/filings/0000310764-25-000129.md) | [14.8](/filings/0000310764-26-000061.md) | [13.3](/filings/0000310764-26-000031.md) | [14.4](/filings/0000310764-26-000050.md) | [14.2](/filings/0000310764-26-000061.md) |
| Total assets | $bn | [39.9](/filings/0000310764-25-000023.md) | [39.4](/filings/0000310764-24-000064.md) | [39.1](/filings/0000310764-24-000098.md) | [43.8](/filings/0000310764-24-000115.md) | [43.0](/filings/0000310764-26-000010.md) | [46.0](/filings/0000310764-25-000075.md) | [46.3](/filings/0000310764-25-000107.md) | [47.1](/filings/0000310764-25-000129.md) | [47.8](/filings/0000310764-26-000061.md) | [46.3](/filings/0000310764-26-000031.md) | [47.9](/filings/0000310764-26-000050.md) | [47.2](/filings/0000310764-26-000061.md) |
| Current liabilities | $bn | [7.9](/filings/0000310764-25-000023.md) | [7.0](/filings/0000310764-24-000064.md) | [6.9](/filings/0000310764-24-000098.md) | [7.7](/filings/0000310764-24-000115.md) | [7.6](/filings/0000310764-26-000010.md) | [7.9](/filings/0000310764-25-000075.md) | [7.3](/filings/0000310764-25-000107.md) | [7.4](/filings/0000310764-25-000129.md) | [7.8](/filings/0000310764-26-000061.md) | [6.3](/filings/0000310764-26-000031.md) | [6.7](/filings/0000310764-26-000050.md) | [6.5](/filings/0000310764-26-000061.md) |
| Total liabilities | $bn | [21.3](/filings/0000310764-25-000023.md) | [20.2](/filings/0000310764-24-000064.md) | [19.4](/filings/0000310764-24-000098.md) | [23.7](/filings/0000310764-24-000115.md) | [22.3](/filings/0000310764-26-000010.md) | [25.1](/filings/0000310764-25-000075.md) | [25.1](/filings/0000310764-25-000107.md) | [25.3](/filings/0000310764-25-000129.md) | [25.4](/filings/0000310764-26-000061.md) | [23.3](/filings/0000310764-26-000031.md) | [23.9](/filings/0000310764-26-000050.md) | [23.8](/filings/0000310764-26-000061.md) |
| Long-term debt | $bn | [10.9](/filings/0000310764-25-000023.md) | [10.8](/filings/0000310764-24-000064.md) | [10.1](/filings/0000310764-24-000098.md) | [13.3](/filings/0000310764-24-000115.md) | [12.2](/filings/0000310764-26-000010.md) | [14.4](/filings/0000310764-25-000075.md) | [14.8](/filings/0000310764-25-000107.md) | [14.8](/filings/0000310764-25-000129.md) | [14.9](/filings/0000310764-26-000061.md) | [14.2](/filings/0000310764-26-000031.md) | [14.2](/filings/0000310764-26-000050.md) | [14.2](/filings/0000310764-26-000061.md) |
| Current portion of debt | $bn | [2.1](/filings/0000310764-25-000023.md) | [2.1](/filings/0000310764-24-000064.md) | [2.1](/filings/0000310764-24-000098.md) | [2.2](/filings/0000310764-24-000115.md) | [1.4](/filings/0000310764-26-000010.md) | [2.4](/filings/0000310764-25-000075.md) | [1.8](/filings/0000310764-25-000107.md) | [1.8](/filings/0000310764-25-000129.md) | [1.0](/filings/0000310764-26-000061.md) | [0.5](/filings/0000310764-26-000031.md) | [0.8](/filings/0000310764-26-000050.md) | [0.8](/filings/0000310764-26-000061.md) |
| Short-term borrowings | $bn | [0.0](/filings/0000310764-24-000024.md) | [0.0](/filings/0000310764-24-000064.md) | [0.0](/filings/0000310764-24-000098.md) | [0.0](/filings/0000310764-24-000115.md) | [0.0](/filings/0000310764-25-000023.md) | [0.0](/filings/0000310764-25-000075.md) | [0.0](/filings/0000310764-25-000107.md) | [0.0](/filings/0000310764-25-000129.md) | [0.0](/filings/0000310764-26-000061.md) | not reported | [0.3](/filings/0000310764-26-000050.md) | [0.3](/filings/0000310764-26-000061.md) |
| Shareholders' equity | $bn | [18.6](/filings/0000310764-26-000010.md) | [19.2](/filings/0000310764-25-000075.md) | [19.8](/filings/0000310764-25-000107.md) | [20.1](/filings/0000310764-25-000129.md) | [20.6](/filings/0000310764-26-000010.md) | [20.9](/filings/0000310764-26-000031.md) | [21.2](/filings/0000310764-26-000050.md) | [21.8](/filings/0000310764-26-000061.md) | [22.4](/filings/0000310764-26-000061.md) | [23.0](/filings/0000310764-26-000031.md) | [24.0](/filings/0000310764-26-000050.md) | [23.5](/filings/0000310764-26-000061.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:DebtCurrent
- Short-term borrowings: us-gaap:CommercialPaper
- Shareholders' equity: us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [1,528 d](/filings/0000310764-26-000010.md) | [204](/filings/0000310764-25-000075.md) | [633 d](/filings/0000310764-25-000107.md) | [1,474 d](/filings/0000310764-25-000129.md) | [1,931 d](/filings/0000310764-26-000010.md) | [250](/filings/0000310764-26-000031.md) | [1,111 d](/filings/0000310764-26-000050.md) | [1,540 d](/filings/0000310764-26-000061.md) | [2,143 d](/filings/0000310764-26-000010.md) | [581](/filings/0000310764-26-000031.md) | [1,261 d](/filings/0000310764-26-000050.md) | [1,461 d](/filings/0000310764-26-000061.md) |
| Capital expenditure | $m | [145 d](/filings/0000310764-26-000010.md) | [167](/filings/0000310764-25-000075.md) | [152 d](/filings/0000310764-25-000107.md) | [170 d](/filings/0000310764-25-000129.md) | [266 d](/filings/0000310764-26-000010.md) | [123](/filings/0000310764-26-000031.md) | [183 d](/filings/0000310764-26-000050.md) | [187 d](/filings/0000310764-26-000061.md) | [268 d](/filings/0000310764-26-000010.md) | [166](/filings/0000310764-26-000031.md) | [202 d](/filings/0000310764-26-000050.md) | [237 d](/filings/0000310764-26-000061.md) |
| Dividends paid | $m | [285 d](/filings/0000310764-26-000010.md) | [304](/filings/0000310764-25-000075.md) | [305 d](/filings/0000310764-25-000107.md) | [305 d](/filings/0000310764-25-000129.md) | [305 d](/filings/0000310764-26-000010.md) | [320](/filings/0000310764-26-000031.md) | [321 d](/filings/0000310764-26-000050.md) | [322 d](/filings/0000310764-26-000061.md) | [321 d](/filings/0000310764-26-000010.md) | [337](/filings/0000310764-26-000031.md) | [337 d](/filings/0000310764-26-000050.md) | [338 d](/filings/0000310764-26-000061.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividends
- Share repurchases: not reported

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [383](/filings/0000310764-24-000064.md) | [384](/filings/0000310764-24-000098.md) | [384](/filings/0000310764-24-000115.md) | [385](/filings/0000310764-25-000075.md) | [385](/filings/0000310764-25-000107.md) | [386](/filings/0000310764-25-000129.md) | [386](/filings/0000310764-26-000031.md) | [386](/filings/0000310764-26-000050.md) | [387](/filings/0000310764-26-000061.md) | [387](/filings/0000310764-26-000031.md) | [386](/filings/0000310764-26-000050.md) | [385](/filings/0000310764-26-000061.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 380,691,004 at 2026-09-30, from the cover of the [10-Q filed 2026-10-30](/filings/0000310764-26-000061.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 31, 2026, 12:17 ET. No prices; not investment advice.